Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Lancet Oncology

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(14)70162-7PMID 24831979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts.

  2013cited by this paper
• A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer

  2013cited by this paper
• Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

  2012cited by this paper
• SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.

  2012cited by this paper
• Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial

  2012cited by this paper
• Randomized clinical trials with biomarkers: design issues.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503

  2010cited by this paper
• Issues in Using Progression-Free Survival When Evaluating Oncology Products

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Issues in using progression-free survival when evaluating oncology products.

  2009cited by this paper
• Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2008cited by this paper
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  2008cited by this paper
• Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

  2007cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2000cited by this paper
• Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcome

  1993cited by this paper
• Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected].

  1993cited by this paper

• Emerging biomarkers for early detection of lung cancer

  2025cites this paper
• Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database

  2025cites this paper
• The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions

  2024cites this paper
• A review on trends in development and translation of omics signatures in cancer

  2024cites this paper
• Precautions to Consider in the Analysis of Prognostic and Predictive Indices

  2024cites this paper
• Prognostic value of circulating proteins at diagnosis among patients with lung cancer: a comprehensive analysis by smoking status

  2024cites this paper
• Increased c‑SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma

  2023cites this paper
• High-throughput proteomics profiling-derived signature associated with chemotherapy response and survival for stage II/III colorectal cancer

  2023cites this paper
• Evaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosis

  2023cites this paper
• Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance

  2023influential citation
• The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer

  2023cites this paper
• Molecular & Translational Biology of the Blood-Based VeriStrat(R) Proteomic Test Used in Cancer Immunotherapy Treatment Guidance

  2022cites this paper
• The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment

  2022influential citation
• Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer

  2022cites this paper
• Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung.

  2022cites this paper
• Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy

  2022cites this paper
• Toxicity Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Patients with Lung Cancer: A Systematic Review and Network Meta-Analysis.

  2021cites this paper
• Current and future research efforts in oligometastatic non-small cell lung cancer—a systematic review

  2021cites this paper
• Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer

  2021cites this paper
• A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

  2021cites this paper
• Explaining multivariate molecular diagnostic tests via Shapley values

  2021influential citation
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib

  2021cites this paper
• Clinical Significance of a Circulating Tumor Cell-based Classifier in Stage IB Lung Adenocarcinoma

  2021cites this paper
• Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib

  2020influential citation
• Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management

  2020cites this paper
• Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

  2020cites this paper
• Non-Small Cell Lung Cancer

  2020cites this paper
• Pharmacogenetic testing: 5 Questions

  2020cites this paper
• A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

  2020cites this paper
• Analysis of Proteomic and Metabolomic Patterns for Cancer Detection, Risk, Prognosis, or Treatment Selection

  2020cites this paper
• Cancer of the Lung

  2020cites this paper
• Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests

  2020cites this paper
• Matrix-assisted laser desorption ionisation (MALDI) mass spectrometry (MS): basics and clinical applications

  2020cites this paper
• Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach

  2020cites this paper
• Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer

  2020cites this paper
• Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis

  2020cites this paper
• Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy

  2020influential citation
• Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis

  2020cites this paper
• A proposal for score assignment to characterize biological processes from mass spectral analysis of serum

  2020cites this paper
• Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib

  2019cites this paper
• Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.

  2019cites this paper
• Circulating biomarkers for high-grade glioma.

  2019cites this paper
• Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

  2019cites this paper
• Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib

  2019cites this paper
• Exploration of Proteins Involved in Acquisition of Resistance to Cetuximab

  2019cites this paper
• L-Lactate dehydrogenase B may be a predictive marker for sensitivity to anti-EGFR monoclonal antibodies in colorectal cancer cell lines.

  2019cites this paper
• An overview on G protein-coupled receptor-induced signal transduction in Acute Myeloid Leukemia.

  2019cites this paper
• Plasma fibronectin levels identified via quantitative proteomics profiling predicts hepatitis B surface antigen seroclearance in chronic hepatitis B.

  2019cites this paper
• Companion and Complementary Diagnostics by Mass Spectrometry

  2019cites this paper
• Personalized Medicine in Oncology Drug Development

  2019cites this paper
• [Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data].

  2019cites this paper
• Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.

  2019cites this paper
• A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.

  2019cites this paper
• The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy☆

  2019cites this paper
• The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.

  2019cites this paper
• Clinical Trial The clinical role of VeriStrat testing in patients with advanced non e small cell lung cancer considered unfit for first-line platinum-based chemotherapy *

  2019cites this paper
• Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer

  2019cites this paper
• The Translational Status of Cancer Liquid Biopsies

  2019cites this paper
• Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy.

  2019cites this paper
• Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib

  2019cites this paper
• Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors

  2018cites this paper
• Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis

  2018cites this paper
• Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer

  2018cites this paper
• Serum peptide expression and treatment responses in patients with advanced non-small-cell lung cancer.

  2018cites this paper
• Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 – 2013

  2018cites this paper
• The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

  2018cites this paper
• Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures

  2018cites this paper
• Proteomics biomarkers for solid tumors: Current status and future prospects.

  2018cites this paper
• Single Cell Proteomics for Molecular Targets in Lung Cancer: High-Dimensional Data Acquisition and Analysis.

  2018cites this paper
• Single Cell Biomedicine

  2018influential citation
• Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.

  2018cites this paper
• Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

  2018cites this paper
• Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues.

  2018cites this paper
• Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.

  2017cites this paper
• Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non e small-cell Lung Cancer

  2017cites this paper
• Erlotinib versus chemotherapy ( docetaxel / pemetrexed ) as second-line therapy in advanced non-small cell lung cancer : a meta-analysis

  2017influential citation
• Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small‐cell Lung Cancer

  2017cites this paper
• Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy

  2017influential citation
• Mass spectrometry protein tests: ready for prime time (or not)

  2017cites this paper
• Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis

  2017cites this paper
• Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

  2017cites this paper
• Biophysical technologies for understanding circulating tumor cell biology and metastasis.

  2017cites this paper
• Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer.

  2017cites this paper
• Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer

  2017cites this paper
• Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS

  2017cites this paper
• Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer

  2017cites this paper
• Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.

  2017cites this paper
• Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints

  2017cites this paper
• Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?

  2017cites this paper
• Second-line therapy of squamous non-small cell lung cancer: an evolving landscape

  2017influential citation
• Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial

  2017cites this paper
• Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.

  2017cites this paper
• Pharmacogenetic Testing

  2017cites this paper
• Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.

  2017cites this paper
• Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

  2017cites this paper
• Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.

  2017cites this paper
• Tumor Profiling, Gene Expression Assays and Molecular Diagnostic Testing for Hematology/Oncology Indications

  2017cites this paper
• Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM)

  2017cites this paper
• Top-down mass spectrometric immunoassay for human insulin and its therapeutic analogs.

  2017cites this paper
• Correcting Estimation Bias in Randomized Clinical Trials With a Test of Treatment-by-Biomarker Interaction

  2017cites this paper